▶ About us
▶ News & Events
▶ For Physicians
▶ How you can help
▶ Site Map
Sign up for our mailing list!
Visit our Facebook page
The Benefits of Exercise
Fetal Transplant Study
Thalassemia Adoption Clinic
Sign up for our newsletter
Story of an Alpha Thalassemia Baby

Treating Thalassemia: Chelation Therapy - L1 (Ferriprox)

Treating Thalassemia
▶ DNA Testing
▶ Transfusion
▶ Chelation
    » Introduction
    » Desferal
        --Desferal guide
    » Exjade
    » L1
    » Combination
▶ Iron and the Pituitary Gland
▶ Splenectomy
▶ Thromboembolic disease
▶ Hemoglobin H disease:
    » Overview
    » Guidelines
▶ Iron Measurement
▶ SQUIDS Across the Globe
▶ Bone Health
▶ Evaluation timetable
▶ Bone marrow transplant
    » HLA genetics
    » BMT factsheet
▶ Hydroxyurea
▶ Standard of Care Guidelines (2012)
▶ Non-transfusion-dependent thalassemia: TIF guidelines
▶ Non-transfusion-dependent thalassemia: Review
Thalassemia Standard-of-Care Guidelines
(mobile optimized)
▶ Intrauterine Therapy for Alpha Thal Major

▶ Fetal Transplant Study
Thalassemia Management Checklists
PDF brochures:
    » Managing Transfusion Therapy
    » Monitoring Iron Overload in TDT
    » Monitoring Deferasirox Therapy

Thalassemia specialty care centers in the Western United States


Treatment with deferiprone (L1/Ferriprox)
Deferiprone (L1, Ferriprox) has been approved for use in several countries for many years and recently received FDA approval for patients who are not effectively chelated with standard therapy. Deferiprone reduces or maintains total body iron stores in the majority of patients. Studies suggest that deferiprone may be more effective than deferoxamine in reducing cardiac iron. Deferiprone in combination with deferoxamine may decrease the risk of cardiac disease and improve cardiac function. Studies in Europe suggest that deferiprone, particularly in combination with deferoxamine, is beneficial in patients with iron cardiomyopathy and cardiac dysfunction. The standard therapeutic daily dose is 75 mg/kg given three times daily and may be increased to 100 mg/kg three times a day in high-risk patients.

The major side effects of deferiprone include gastrointestinal symptoms, joint pain, and neutropenia. Due to the risk of agranulocytosis and associated rare deaths, weekly white blood cell counts are required for all patients receiving this drug. Zinc deficiency may occur particularly with deferiprone and require supplementation.

Northern California Comprehensive Thalassemia Center
UCSF Benioff Children's Hospital Oakland
747 52nd Street, Oakland CA 94609   •   Phone: (510) 428-3347   •   Fax: (510) 450-5647
© 2003-2012 Children's Hospital & Research Center Oakland
Facebook logo Twitter logo Youtube logo Blogger logo
| Home | Our Program | Contact Us | For physicians | What is thalassemia? | Genetics | Treatment | Research | Living with thalassemia | Site Map |